SGLT2 inhibitors may offer additional benefits 47-49; however, data on their safety and effects in patients with ADPKD are currently lacking, as these patients were excluded from SGLT2 inhibitors trials. The gene discussed is SLC5A2; the disease is autosomal dominant polycystic kidney disease.